The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: A meta-analysis of randomized controlled trials

American Journal of Clinical Nutrition

Volumn 106, Issue 3, 2017, Pages 921-929

  Dibaba, Daniel T ^a   Xun, Pengcheng ^a   Song, Yiqing ^b   Rosanoff, Andrea ^c   Shechter, Michael ^d   He, Ka ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Center for Magnesium Education and Research   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Blood pressure; Cardiovascular diseases; Insulin resistance; Magnesium; Magnesium supplementation; Meta analysis; Noncommunicable chronic diseases; Prediabetes; Supplementation; Type 2 diabetes

Indexed keywords

MAGNESIUM; MAGNESIUM ASPARTATE; MAGNESIUM CHLORIDE; PYROGLUTAMATE MAGNESIUM;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; MALIGNANT NEOPLASM; META ANALYSIS; MINERAL SUPPLEMENTATION; NON COMMUNICABLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; ADULT; AGED; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; HYPERTENSION; MALE; MIDDLE AGED;

ADULT; AGED; BLOOD PRESSURE; CHRONIC DISEASE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MAGNESIUM; MALE; MIDDLE AGED; NUTRITION THERAPY; PREDIABETIC STATE;

EID: 85028705486     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.117.155291     Document Type: Article

References (47)

1. Teragawa H, Matsuura H, Chayama K, Oshima T. Mechanisms responsible for vasodilation upon magnesium infusion in vivo: clinical evidence. Magnes Res 2002;15:241-6.
2. Satake K, Lee JD, Shimizu H, Uzui H, Mitsuke Y, Yue H, Ueda T. Effects of magnesium on prostacyclin synthesis and intracellular free calcium concentration in vascular cells. Magnes Res 2004;17:20-7.
3. Feyh A, Bracero L, Lakhani HV, Santhanam P, Shapiro JI, Khitan Z, Sodhi K. Role of dietary components in modulating hypertension. J Clin Exp Cardiolog 2016;7;pii:433.
4. Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L, Pineo A, Busardo A, Paolisso G. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med 2003;24:39-52.
5. Cunha AR, Umbelino B, Correia ML, Neves MF. Magnesium and vascular changes in hypertension. Int J Hypertens 2012;2012:754250.
6. Geiger H, Wanner C. Magnesium in disease. Clin Kidney J 2012;5 Suppl 1:i25-38.
7. Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnes Res 2010;23:27-40.
8. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr 2012;66:411-8.
9. Jee SH, Miller ER III, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a metaanalysis of randomized clinical trials. Am J Hypertens 2002;15:691-6.
10. Rosanoff A, PlessetMR. Oral magnesium supplements decrease high blood pressure (SBP.155 mmHg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analysis. Magnes Res 2013;26:93-9.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
12. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, Song Y. Effects of magnesium supplementation on blood pressure: a metaanalysis of randomized double-blind placebo-controlled trials. Hypertension 2016;68:324-33.
13. Guerrero-Romero F, Rodríguez-Morán M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial. J Hum Hypertens 2009;23:245-51.
14. Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res 2010;23:131-7.
15. de Valk HW, Verkaaik R, van Rijn HJ, Geerdink RA, Struyvenberg A. Oral magnesium supplementation in insulin-requiring type 2 diabetic patients. Diabet Med 1998;15:503-7.
16. Mooren FC, Kruger K, Volker K, Golf SW, Wadepuhl M, Kraus A. Oral magnesium supplementation reduces insulin resistance in nondiabetic subjects - a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 2011;13:281-4.
17. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003;26:1147-52.
18. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebocontrolled trial. Arch Med Res 2014;45:388-93.
19. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial. Arch Med Res 2014;45:325-30.
20. Guerrero-Romero F, Tamez-Perez HE, González-González G, Salinas-Martínez AM, Montes-Villarreal J, Trevino-Ortiz JH, Rodríguez-Morán M. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebocontrolled randomized trial. Diabetes Metab 2004;30:253-8.
21. Cahill F, Shahidi M, Shea J, Wadden D, Gulliver W, Randell E, Vasdev S, Sun G. High dietary magnesium intake is associated with low insulin resistance in the Newfoundland population. PLoS One 2013;8:e58278.
22. Hruby A, O'Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imaging 2014;7:59-69.
23. Barragán-Rodríguez L, Rodríguez-Morán M, Guerrero-Romero F. Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes Res 2008;21:218-23.
24. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102:2353-8.
25. Simental-Mendía LE, Rodríguez-Morán M, Reyes-Romero MA, Guerrero-Romero F. No positive effect of oral magnesium supplementation in the decreases of inflammation in subjects with prediabetes: a pilot study. Magnes Res 2012;25:140-6.
26. Sullivan LM. Essentials of biostatistics in public health. 2nd ed. Riegelman R, editor. Burlington (MA): Jones & Bartlett Learning; 2012.
27. Fu R, Vandermeer BW, Shamliyan TA, O'Neil ME, Yazdi F, Fox SH, Morton SC. Handling continuous outcomes in quantitative synthesis. In: Methods guide for effectiveness and comparative effectiveness reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629-34.
29. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
30. Hardy ST, Loehr LR, Butler KR, Chakladar S, Chang PP, Folsom AR, Heiss G, MacLehose RF, Matsushita K, Avery CL. Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control. J Am Heart Assoc 2015;4:e002276.
31. Sever PS, Poulter NR, Elliott WJ, Jonsson MC, Black HR, Sever PS, Poulter NR, Elliott WJ, Jonsson MC, Black HR. Blood pressure reduction is not the only determinant of outcome. Circulation 2006;113:2754-72, discussion 73-4.
32. Kupetsky-Rincon EA, Li Q, Uitto J. Magnesium reduces carotid intima-media thickness in a mouse model of pseudoxanthoma elasticum: a novel treatment biomarker. Clin Transl Sci 2012;5:259-64.
33. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008;40:1075-82.
34. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A. Effect of magnesium supplementation on carotid intimamedia thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 2013;69:309-16.
35. Dashti GR, Rezaei M, Adibi A, Golshan Iranpour F. Assessment of serum magnesium level and its relation with atherosclerotic carotid intima media thickness in post-menopausal women. Int J of Biomed & Adv Res 2015;3:203-11.
36. Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, Altura BM. Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA 1990;87:1840-4.
37. Larsson SC, Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med 2007;262:208-14.
38. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 2011;34:2116-22.
39. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006;23:1050-6.
40. Lago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract End Met 2007;3:667.
41. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8.
42. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47:201-10.
43. Nosadini R. Hypertension and renal complications in type 2 diabetes. Semin Vasc Med 2002;2:109-19.
44. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris SB. Hypertension in people with type 2 diabetes: update on pharmacologic management. Can Fam Physician 2011;57:997-1002.
45. Qu X, Jin F, Hao Y, Li H, Tang T, Wang H, Yan W, Dai K. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS One 2013;8:e57720.
46. Chiuve SE, Sun Q, Curhan GC, Taylor EN, Spiegelman D, Willett WC, Manson JE, Rexrode KM, Albert CM. Dietary and plasma magnesium and risk of coronary heart disease among women. J Am Heart Assoc 2013;2:e000114.
47. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and noncardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014;85:174-81.